# Dose Escalation Study of AUY922 in Advanced Solid Malignancies in Japan

> **NCT01132625** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 37 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** AUY922

## Key facts

- **NCT ID:** NCT01132625
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2020-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01132625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01132625, "Dose Escalation Study of AUY922 in Advanced Solid Malignancies in Japan". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01132625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*